The TRINITY study: Twitter discussion from a respirology journal club - Authors' reply

Affiliations

¹ Division of Infection, Immunity, and Respiratory Medicine, University of Manchester, Manchester M13 9NT, UK. Electronic address: jorgen.vestbo@manchester.ac.uk.

Comment

Jørgen Vestbo et al. Lancet Respir Med. 2017 Jul.

. 2017 Jul;5(7):e26.

doi: 10.1016/S2213-2600(17)30230-8.

¹ Division of Infection, Immunity, and Respiratory Medicine, University of Manchester, Manchester M13 9NT, UK. Electronic address: jorgen.vestbo@manchester.ac.uk.

No abstract available

Comment on

Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D. Vestbo J, et al. Lancet. 2017 May 13;389(10082):1919-1929. doi: 10.1016/S0140-6736(17)30188-5. Epub 2017 Apr 3. Lancet. 2017. PMID: 28385353 Clinical Trial.
The TRINITY study: Twitter discussion from a respirology journal club.
Brijbassi M, Anand A, Stanbrook M. Brijbassi M, et al. Lancet Respir Med. 2017 Jul;5(7):e25. doi: 10.1016/S2213-2600(17)30231-X. Lancet Respir Med. 2017. PMID: 28664864 No abstract available.